ESMO 2017 | An exciting new combination to treat advanced solid tumors
Paolo Ascierto, MD from the National Tumour Institute Fondazione G. Pascale, Naples, Italy talks to us about a Phase I clinical trial (NCT02966548), presented at the European Society for Medical Oncology (ESMO) 2017 conference, which he found particularly interesting. This study examined the efficacy of nivolumab and relatimab in the treatment of patients with advanced solid tumors. Prof. Ascierto discusses the preliminary data and explains why this new combination of agents is so exciting. This interview was recorded at ESMO 2017, held in Madrid, Spain.
Get great new content delivered to your inboxSign up